Advertisement

Journal of Neuro-Oncology

, Volume 100, Issue 1, pp 43–49 | Cite as

CDC25A mRNA levels significantly correlate with Ki-67 expression in human glioma samples

  • Yoji Yamashita
  • Isao Kasugai
  • Masami Sato
  • Nobuhiro Tanuma
  • Ikuro Sato
  • Miyuki Nomura
  • Katsumi Yamashita
  • Yukihiko Sonoda
  • Toshihiro Kumabe
  • Teiji Tominaga
  • Ryuichi Katakura
  • Hiroshi ShimaEmail author
Laboratory Investigation - Human/Animal Tissue

Abstract

Cell division cycle 25 (CDC25) phosphatases are cell-cycle regulatory proteins which are overexpressed in a significant number of human cancers. This study evaluated the role of CDC25 phosphatases in human glioma proliferation. Upregulation of CDC25A was observed in human glioma specimens and human glioma cell lines. Comparison of expression levels of CDC25A and CDC25B messenger ribonucleic acid (RNA) to Ki-67 labeling index in glioma tissues found that Ki-67 labeling index was significantly correlated with the expression of CDC25A, but not with that of CDC25B. Depletion of CDC25A by small interfering RNA and inhibition of CDC25 suppressed cell proliferation and induced apoptosis in glioma cell lines, indicating that CDC25A is a potential target for the development of new therapy for glioma.

Keywords

CDC25A Glioma Ki-67 Protein phosphatase 

Notes

Acknowledgments

This work was supported in part by Grants-in-aid for Scientific Research (C) to Y.Y. and H.S. and for Exploratory Research to R.K. provided by the Japan Society for the Promotion of Science.

References

  1. 1.
    Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170:1445–1453CrossRefPubMedGoogle Scholar
  2. 2.
    Sathornssumetee S, Reardon DA, Desjardins A, Quinn JA, Vredenburgh JJ, Rich JN (2007) Molecularly targeted therapy for malignant glioma. Cancer 110:13–24CrossRefGoogle Scholar
  3. 3.
    Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–1812CrossRefPubMedGoogle Scholar
  4. 4.
    Rich JN, Hans C, Jones B, Iversen ES, McLendon RE, Rasheed BK, Dobra A, Dressman HK, Bigner DD, Nevins JR, West M (2005) Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res 65:4051–4058CrossRefPubMedGoogle Scholar
  5. 5.
    Faria MH, Gonçalves BP, do Patrocínio RM, de Moraes-Filho MO, Rabenhorst SH (2006) Expression of Ki-67, topoisomerase IIalpha and c-MYC in astrocytic tumors: correlation with the histopathological grade and proliferative status. Neuropathology 26:519–527CrossRefPubMedGoogle Scholar
  6. 6.
    Johannessen AL, Torp SH (2006) The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathol Oncol Res 12:143–147CrossRefPubMedGoogle Scholar
  7. 7.
    Boutros R, Dozier C, Ducommun B (2006) The when and wheres of CDC25 phosphatases. Curr Opin Cell Biol 18:185–191CrossRefPubMedGoogle Scholar
  8. 8.
    Boutros R, Lobjois V, Ducommun B (2007) CDC25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer 7:495–507CrossRefPubMedGoogle Scholar
  9. 9.
    Kiyokawa H, Ray D (2008) In vivo roles of CDC25 phosphatases: biological insight into the anti-cancer therapeutic targets. Anticancer Agents Med Chem 8:826–832Google Scholar
  10. 10.
    Lazo JS, Wipf P (2008) Is Cdc25 a druggable target? Anticancer Agents Med Chem 8:837–842PubMedGoogle Scholar
  11. 11.
    Brezak MC, Quaranta M, Mondésert O, Galcera MO, Lavergne O, Alby F, Cazales M, Baldin V, Thurieau C, Harnett J, Lanco C, Kasprzyk PG, Prevost GP, Ducommun B (2004) A novel synthetic inhibitor of CDC25 phosphatases: BN82002. Cancer Res 64:3320–3325CrossRefPubMedGoogle Scholar
  12. 12.
    Brezak MC, Quaranta M, Contour-Galcera MO, Lavergne O, Mondesert O, Auvray P, Kasprzyk PG, Prevost GP, Ducommun B (2005) Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases. Mol Cancer Ther 4:1378–1387CrossRefPubMedGoogle Scholar
  13. 13.
    Nakabayashi H, Hara M, Shimizu K (2006) Prognostic significance of CDC25B expression in gliomas. J Clin Pathol 59:725–728CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Yoji Yamashita
    • 1
    • 2
  • Isao Kasugai
    • 1
  • Masami Sato
    • 1
  • Nobuhiro Tanuma
    • 1
  • Ikuro Sato
    • 3
  • Miyuki Nomura
    • 1
  • Katsumi Yamashita
    • 4
  • Yukihiko Sonoda
    • 5
  • Toshihiro Kumabe
    • 5
  • Teiji Tominaga
    • 5
  • Ryuichi Katakura
    • 2
  • Hiroshi Shima
    • 1
    Email author
  1. 1.Division of Cancer ChemotherapyMiyagi Cancer Center Research InstituteNatoriJapan
  2. 2.Department of NeurosurgeryMiyagi Cancer CenterNatoriJapan
  3. 3.Section of Clinical ResearchMiyagi Cancer Center Research InstituteNatoriJapan
  4. 4.Division of Life Science, Graduate School of Natural Science and TechnologyKanazawa UniversityKanazawaJapan
  5. 5.Department of NeurosurgeryTohoku University Graduate School of MedicineSendaiJapan

Personalised recommendations